Vical, Inc. (VICL)
Loading...
Symbols:
VICL Forum Topics
- All Comments on VICL
- General Discussion on VICL
- Cancer Stocks Plunge Following ASCO Meeting [view article]
- Cancer Stocks on the Go: Winners and Losers [view article]
- Russian Roulette Pays Off for Antigenics [view article]
- Cancer Stocks Slide Again [view article]
- Cancer Stocks Soar With Annual ASCO Meeting [view article]
- Biotech Day In Review: Genentech Beats Estimates Slightly [view article]
loading ...Recent VICL Articles
- Russian Roulette Pays Off for Antigenics
- Cancer Stocks: Tracking the Market
- Cancer Stocks: The Bleeding Slows
- Cancer Stocks Slide Again
- Cancer Stocks Plunge Following ASCO Meeting
- Cancer Stocks Soar With Annual ASCO Meeting
- Cancer Stocks on the Go: Winners and Losers
- Biotech Day In Review: Genentech Beats Estimates Slightly
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Cancer Stocks Plunge Following ASCO Meeting [view article]
EXCELLENT JOB, ReplyCancer Stocks on the Go: Winners and Losers [view article]
I agree with paviov, However I would like to know about the new developments the phase II and III studies that are going well, where is the advancement taking place, how close to a cure, what company has the potential winning drug ?? ReplyRussian Roulette Pays Off for Antigenics [view article]
DNDN should try to get approval from russia, india middle east....American can fly get treatment.They can boost their economy. ReplyRussian Roulette Pays Off for Antigenics [view article]
I guess Big Pharma has not managed to bribe the right people in the Russian drug approval process. Their problem is that US methods of persuasion do not transfer to the Russian economy. Maybe DNDN, etc. will wise up and take their research someplace other than the US so that their products can be delivered to people who so desparately need them in order to survive. ReplyRussian Roulette Pays Off for Antigenics [view article]
Of course..we don't know if its a vaccine..or a wanna be vaccine. We don't know what its clinical trials looked like in the United States because of a lack of article information. We don't know that the Russians approved this drug--whatever that means in Russia--for the publicity or merely to make money at unfortunate people's expense. Although...given the high regard in which Russia holds consumer protections and rights I'm sure its a fabulous drug.... ReplyRussian Roulette Pays Off for Antigenics [view article]
Good for Russia....at least common sense still exists somewhere in the world. It's too bad the FDA doesn't have any. ReplyEditors
General Discussion on VICL
Is this a buy or a sell? ReplyBrochstein
Cancer Stocks Slide Again [view article]
I wanted to point out an error in the article - GNVC is developing a pancreatic cancer treatment (not vaccine). ReplyBrochstein
Cancer Stocks Plunge Following ASCO Meeting [view article]
Miles, I have a negative bias towards small biotech companies, especially ones like this that have a terrible history of underperforming the stock market, generating losses and diluting with equity issuance. That isn't to say that one might find a diamond in the garbage can, but, I think that one is actually more likely to find a diamond in the garbage can. If one of these companies is creating a truly novel, revolutionary treatment, I personally believe that an investor would have plenty of time to buy later at a higher price and still make a ton of money.Note, I don't have an opinion specifically on Insmed other than my general observations in the above paragraph. Reply
s
Cancer Stocks Plunge Following ASCO Meeting [view article]
Dear Sir,What is your current opinion on Insmed?
Thank you very much,
Miles Roberts Reply
Cancer Stocks Soar With Annual ASCO Meeting [view article]
Your table is too over-crowded to be useful. Next time skip the industry, HQ city and state as it is meaningless except for job seekers. Nice try though. ReplyBrochstein
Cancer Stocks on the Go: Winners and Losers [view article]
You get what you pay for, then. If I could publish this list in advance, well, I would be doing it from my boat in the Bahamas!Many investors look at price action in order to alert them to areas where they should be focused. Is the move overdone (take profits), or is it sustainable (consider buying). Reply
Cancer Stocks on the Go: Winners and Losers [view article]
Telling me about stocks after the fact don't do shit for me!!! ReplyBiotech Day In Review: Genentech Beats Estimates Slightly [view article]
OVERLOOKED NOW BY WALL STREET BUT THEY'RE IN FOR A BIG SURPRISE WHEN THESE STOCKS BLOSSOM THIS YEAR. IN THE NEXT 8 MONTHS EACH STOCK WILL HAVE MATURED INTO A VERY ATTRACTIVE INVESTMENT BEAUTY. IT WILL THEN HAVE EYE APPEAL AND THEY'LL HAVE TO PAY A PREMIUM THEN TO OWN IT.APRIL 12 DIRTY DOZEN BIOTECH STOCKS!
ARRY $12.83 BMRN $17.59 IDEV $7.6 ISTA $8.88 INCY $7.30
ISIS $9.61 SNUS $5.50 AVRX $4.67 SVNT $12.17 NUVO $4.48
ACUS $3.27 XOMA $2.98
EXPLOSIVE GROWTH POTENTIAL & POTENTIAL TAKEOVERS
THESE STOCKS ARE WHAT DREAMS ARE MADE OF.
JT7423 Reply